Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Nov;62(10):1424-1428.
doi: 10.1111/head.14421. Epub 2022 Nov 14.

Refractory glossopharyngeal neuralgia successfully treated with onabotulinumtoxinA: A case report

Katherine T Hamilton  1 , Rachel Seligman  2 , Rachel Blue  3 , John Y K Lee  3
Affiliations
Case Reports

Refractory glossopharyngeal neuralgia successfully treated with onabotulinumtoxinA: A case report

Katherine T Hamilton et al. Headache. 2022 Nov.

Abstract

Background: Glossopharyngeal neuralgia is a rare but severe and disabling pain condition often caused by vascular compression of the glossopharyngeal nerve. Treatment is similar to that of trigeminal neuralgia, but some patients may be refractory to both medical and surgical approaches. Here we present a case of refractory glossopharyngeal neuralgia that responded well to onabotulinumtoxinA (BTX-A).

Case: We report a case of a 65-year-old man with well-controlled human immunodeficiency virus disease with glossopharyngeal neuralgia symptoms since 2015. He had partial response to medications but was limited by side-effects. He underwent microvascular decompression twice with initial relief both times, but experienced recurrence of attacks 1-3 years after each surgery. He was treated with BTX-A using the chronic migraine PREEMPT protocol (i.e., 31-39 injection sites in head and neck muscles), which led to significant relief of his glossopharyngeal neuralgia pain.

Conclusions: This is the first case to our knowledge of glossopharyngeal neuralgia treated with BTX-A. BTX-A can be an effective treatment for glossopharyngeal neuralgia, even when injections are not administered directly over the sensory distribution of the glossopharyngeal nerve.

Keywords: case report; glossopharyngeal neuralgia; onabotulinumtoxinA; refractory; treatment.

PubMed Disclaimer

References

REFERENCES

    1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211. doi: 10.1177/0333102417738202
    1. Tepper SJ. Cranial neuralgias. Continuum (Minneap Minn). 2018;24:1157-1178.
    1. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155:654-662.
    1. Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain. 2009;147:122-127.
    1. Zheng W, Zhao P, Song H, et al. Prognostic factors for long-term outcomes of microvascular decompression in the treatment of glossopharyngeal neuralgia: a retrospective analysis of 97 patients. J Neurosurg. 2021;17:1-8.

Publication types

MeSH terms

LinkOut - more resources